Clinical Trials Directory

Trials / Unknown

UnknownNCT05440591

Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes

Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes- A Randomised Controlled Trial (DMVascular Study)

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Tan Tock Seng Hospital · Academic / Other
Sex
All
Age
30 Years – 65 Years
Healthy volunteers
Accepted

Summary

Trial Design: This is a 12 week randomised controlled open label trial comparing the impact of Dapagliflozin, Metformin and combination therapy on vascular function in newly diagnosed T2DM patients.

Detailed description

Trial Design: This is a 12 week randomised controlled open label trial comparing the impact of Dapagliflozin, Metformin and combination therapy on vascular function in newly diagnosed T2DM patients. Trial Participants: Approximately 150 newly diagnosed T2DM patients with randomization 1:1:1 to Metformin XR 500mg twice daily, Dapagliflozin 10 mg daily or Metformin XR 500/Dapagliflozin 5 mg daily Primary Aim : To evaluate the influence of intervention on vascular function. Secondary Aims: 1. To evaluate the influence on other parameters of vascular function and beds. 2. To evaluate the haemodynamics involving blood pressure regulation. 3. To evaluate the effects of SGLT2i versus Metformin on endothelial interactions (vascular permeability) and leukocyte-endothelial interactions (leukocyte rolling, adherence), endothelial regenerative capacity and other endothelial related pathways.

Conditions

Interventions

TypeNameDescription
DRUGDapagliflozinDapagliflozin 10mg tablets
DRUGMetFORMIN 500 Mg Oral TabletMetformin 500 mg tablets twice daily
DRUGDapagliflozin / metFORMIN PillCombination pill

Timeline

Start date
2019-04-01
Primary completion
2023-05-10
Completion
2023-05-10
First posted
2022-07-01
Last updated
2022-07-01

Locations

1 site across 1 country: Singapore

Source: ClinicalTrials.gov record NCT05440591. Inclusion in this directory is not an endorsement.